Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.52
ALKS's Cash to Debt is ranked higher than
59% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. ALKS: 1.52 )
ALKS' s 10-Year Cash to Debt Range
Min: 0.04   Max: No Debt
Current: 1.52

Equity to Asset 0.73
ALKS's Equity to Asset is ranked higher than
76% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ALKS: 0.73 )
ALKS' s 10-Year Equity to Asset Range
Min: -0.15   Max: 0.9
Current: 0.73

-0.15
0.9
Interest Coverage 1.67
ALKS's Interest Coverage is ranked lower than
53% of the 408 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALKS: 1.67 )
ALKS' s 10-Year Interest Coverage Range
Min: 0.62   Max: 9.81
Current: 1.67

0.62
9.81
F-Score: 7
Z-Score: 8.31
M-Score: -2.82
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 14.21
ALKS's Operating margin (%) is ranked higher than
90% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. ALKS: 14.21 )
ALKS' s 10-Year Operating margin (%) Range
Min: -331.3   Max: 41.29
Current: 14.21

-331.3
41.29
Net-margin (%) 4.34
ALKS's Net-margin (%) is ranked higher than
83% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. ALKS: 4.34 )
ALKS' s 10-Year Net-margin (%) Range
Min: -296.89   Max: 69.37
Current: 4.34

-296.89
69.37
ROE (%) 2.62
ALKS's ROE (%) is ranked higher than
83% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -20.60 vs. ALKS: 2.62 )
ALKS' s 10-Year ROE (%) Range
Min: -1828.02   Max: 54.69
Current: 2.62

-1828.02
54.69
ROA (%) 1.70
ALKS's ROA (%) is ranked higher than
84% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. ALKS: 1.70 )
ALKS' s 10-Year ROA (%) Range
Min: -41.81   Max: 25.44
Current: 1.7

-41.81
25.44
ROC (Joel Greenblatt) (%) 20.63
ALKS's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -243.56 vs. ALKS: 20.63 )
ALKS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -231.02   Max: 116.82
Current: 20.63

-231.02
116.82
Revenue Growth (%) 30.70
ALKS's Revenue Growth (%) is ranked higher than
93% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. ALKS: 30.70 )
ALKS' s 10-Year Revenue Growth (%) Range
Min: -22   Max: 69.1
Current: 30.7

-22
69.1
» ALKS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ALKS Guru Trades in Q3 2013

Steven Cohen 128,699 sh (+33.45%)
Vanguard Health Care Fund 2,864,896 sh (+26.21%)
Murray Stahl 25,000 sh (unchged)
Joel Greenblatt Sold Out
Pioneer Investments 175,180 sh (-16.28%)
Jim Simons 661,686 sh (-16.74%)
Jeff Auxier 37,951 sh (-22.15%)
» More
Q4 2013

ALKS Guru Trades in Q4 2013

Vanguard Health Care Fund 3,672,087 sh (+28.18%)
Pioneer Investments 213,043 sh (+21.61%)
Murray Stahl 25,000 sh (unchged)
Steven Cohen Sold Out
Jeff Auxier 31,851 sh (-16.07%)
Jim Simons 505,586 sh (-23.59%)
» More
Q1 2014

ALKS Guru Trades in Q1 2014

John Burbank 4,651 sh (New)
Steven Cohen 5,591 sh (New)
Vanguard Health Care Fund 5,180,238 sh (+41.07%)
Murray Stahl 25,000 sh (unchged)
Jeff Auxier 29,851 sh (-6.28%)
Pioneer Investments 180,753 sh (-15.16%)
Jim Simons 53,310 sh (-89.46%)
» More
Q2 2014

ALKS Guru Trades in Q2 2014

Ken Fisher 55,309 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with ALKS

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2014-03-31 Add 41.07%0.19%$40.07 - $53.82 $ 44.94-5%5180238
John Burbank 2014-03-31 New Buy0.01%$40.07 - $53.82 $ 44.94-5%4651
Vanguard Health Care Fund 2013-12-31 Add 28.18%0.1%$30.17 - $41.12 $ 44.9422%3672087
Vanguard Health Care Fund 2013-09-30 Add 26.21%0.07%$28.66 - $35.35 $ 44.9438%2864896
Joel Greenblatt 2013-09-30 Sold Out 0.03%$28.66 - $35.35 $ 44.9438%0
Vanguard Health Care Fund 2013-06-30 Add 84.09%0.11%$22.35 - $33.72 $ 44.9454%2269902
Joel Greenblatt 2013-06-30 New Buy0.03%$22.35 - $33.72 $ 44.9454%26624
Vanguard Health Care Fund 2013-03-31 Add 47.24%0.04%$18.52 - $23.81 $ 44.94106%1233024
John Burbank 2012-03-31 Sold Out 0.23%$16.14 - $19.5 $ 44.94173%0
Vanguard Health Care Fund 2012-03-31 New Buy0.07%$16.14 - $19.5 $ 44.94173%787900
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.90
ALKS's P/B is ranked higher than
75% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 5.51 vs. ALKS: 4.90 )
ALKS' s 10-Year P/B Range
Min: 1.66   Max: 379.8
Current: 4.9

1.66
379.8
P/S 10.65
ALKS's P/S is ranked higher than
74% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 19.16 vs. ALKS: 10.65 )
ALKS' s 10-Year P/S Range
Min: 2.19   Max: 35.3
Current: 10.65

2.19
35.3
PFCF 172.90
ALKS's PFCF is ranked higher than
89% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALKS: 172.90 )
ALKS' s 10-Year PFCF Range
Min: 10.27   Max: 196.04
Current: 172.9

10.27
196.04
EV-to-EBIT -1028.15
ALKS's EV-to-EBIT is ranked higher than
56% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALKS: -1028.15 )
ALKS' s 10-Year EV-to-EBIT Range
Min: 3.6   Max: 628
Current: -1028.15

3.6
628
Current Ratio 8.37
ALKS's Current Ratio is ranked higher than
86% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. ALKS: 8.37 )
ALKS' s 10-Year Current Ratio Range
Min: 2.01   Max: 15.4
Current: 8.37

2.01
15.4
Quick Ratio 7.78
ALKS's Quick Ratio is ranked higher than
86% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. ALKS: 7.78 )
ALKS' s 10-Year Quick Ratio Range
Min: 1.95   Max: 15.4
Current: 7.78

1.95
15.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 115.20
ALKS's Price/Net Cash is ranked higher than
73% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 65.19 vs. ALKS: 115.20 )
ALKS' s 10-Year Price/Net Cash Range
Min: 3.39   Max: 113.05
Current: 115.2

3.39
113.05
Price/Net Current Asset Value 36.80
ALKS's Price/Net Current Asset Value is ranked higher than
75% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 44.88 vs. ALKS: 36.80 )
ALKS' s 10-Year Price/Net Current Asset Value Range
Min: 3.39   Max: 157.67
Current: 36.8

3.39
157.67
Price/Tangible Book 9.00
ALKS's Price/Tangible Book is ranked higher than
71% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 8.78 vs. ALKS: 9.00 )
ALKS' s 10-Year Price/Tangible Book Range
Min: 1.25   Max: 336
Current: 9

1.25
336
Price/DCF (Projected) 4.90
ALKS's Price/DCF (Projected) is ranked higher than
92% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALKS: 4.90 )
ALKS' s 10-Year Price/DCF (Projected) Range
Min: 2   Max: 20.95
Current: 4.9

2
20.95
Price/Median PS Value 2.20
ALKS's Price/Median PS Value is ranked higher than
70% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. ALKS: 2.20 )
ALKS' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 14.23
Current: 2.2

0.38
14.23
Earnings Yield (Greenblatt) 0.80
ALKS's Earnings Yield (Greenblatt) is ranked lower than
58% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. ALKS: 0.80 )
ALKS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 27.9
Current: 0.8

0.2
27.9
Forward Rate of Return (Yacktman) 0.15
ALKS's Forward Rate of Return (Yacktman) is ranked higher than
88% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: -10.54 vs. ALKS: 0.15 )
ALKS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -6.1   Max: 2.2
Current: 0.15

-6.1
2.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:8AK.Germany
Alkermes PLC is a biotechnology company. It is engaged in developing, manufacturing and commercializing medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious diseases. It has a diversified portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system disorders such as addiction, schizophrenia and depression. The Company relies solely on its manufacturing facility in Wilmington, Ohio for the manufacture of RISPERDAL CONSTA, VIVITROL, polymer for BYDUREON and some of our product candidates.
» More Articles for NAS:ALKS

Headlines

Articles On GuruFocus.com
wait for positive ea Apr 06 2013 
comment on ALKS Mar 09 2013 
Best Health Care Investor Edward Owens Buys One New Health Care Stock in First Quarter Apr 30 2012 
Weekly CEO Sells Highlight: Herbalife, CNO Financial Group, Alkermes plc, and TransDigm Oct 08 2011 
Alkermes Inc. Reports Operating Results (10-Q) Feb 03 2011 
Weekly Guru Bargains Highlights: SKX, VRX, ALKS, DF, SVU Dec 05 2010 
Alkermes Inc. Reports Operating Results (10-Q) Nov 04 2010 
Alkermes Inc. Reports Operating Results (10-K) May 21 2010 
Alkermes Inc. Reports Operating Results (10-Q) Feb 04 2010 
Opportunistic Coat-tailing Jan 05 2010 


More From Other Websites
Alkermes to Host Conference Call to Discuss Second Quarter 2014 Financial Results Jul 24 2014
Alkermes to Host Conference Call to Discuss Second Quarter 2014 Financial Results Jul 24 2014
Alkermes' Pipeline Development Impresses, Key Updates Ahead Jul 21 2014
Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 8700 for Treatment of Multiple... Jul 17 2014
Alkermes announces initiation of Phase 1 study of ALKS 8700 for treatment of MS Jul 17 2014
Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 8700 for Treatment of Multiple... Jul 17 2014
Alkermes Announces Notices of Allowance for U.S. Patents for Four CNS Pipeline Candidates Jul 09 2014
Alkermes Announces Notices of Allowance for U.S. Patents for Four CNS Pipeline Candidates Jul 09 2014
Momentum names slammed as volatility comes back Jul 08 2014
Alkermes plc (ALKS) Jumps: Stock Rises 5.7% Jun 23 2014
Alkermes' Aripiprazole Lauroxil Looks Promising Jun 19 2014
New Alkermes Schizophrenia Drug -- An Important Advance With Social Benefits Jun 18 2014
Alkermes presents aripiprazole lauroxil phase 3 data Jun 18 2014
Alkermes Progresses with its Late Stage Candidate Jun 11 2014
Alkermes announces initiation of FORWARD-3, FORWARD-4 efficacy studies Jun 10 2014
Alkermes Announces Initiation of FORWARD-3 and FORWARD-4 Efficacy Studies in Pivotal Program for... Jun 10 2014
Alkermes Announces Initiation of FORWARD-3 and FORWARD-4 Efficacy Studies in Pivotal Program for... Jun 10 2014
What's in a Name? Alkermes Thinks Alkeus is too Close for Comfort Jun 09 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide